Aardvark Therapeutics, Inc.
AARD
$4.13
-$0.42-9.14%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -69.87M | -57.59M | -48.77M | -36.64M | -27.72M |
| Total Depreciation and Amortization | 42.00K | 36.00K | 34.00K | 32.00K | 19.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.74M | 3.03M | 1.81M | 945.00K | 881.00K |
| Change in Net Operating Assets | 3.44M | 356.00K | 1.84M | 2.75M | -465.00K |
| Cash from Operations | -61.65M | -54.17M | -45.09M | -32.91M | -27.29M |
| Capital Expenditure | -95.00K | -95.00K | -101.00K | -102.00K | -104.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 97.30M | -49.57M | -85.76M | -115.01M | -124.51M |
| Cash from Investing | 97.21M | -49.67M | -85.86M | -115.12M | -124.62M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 455.00K | 91.64M | 91.53M | 91.52M | 91.52M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 0.00 | 0.00 | 85.00M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -77.00K | -2.39M | -3.56M | -3.67M | -5.65M |
| Cash from Financing | 378.00K | 89.25M | 87.96M | 87.85M | 170.87M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 35.93M | -14.59M | -42.99M | -60.18M | 18.96M |